@conrad, to me it looks like they set out 4 scenarios, which are really only two scenarios with two discount rates for each. But then only picked the lower market scenario with the higher discount rate to arrive at the target valuation.

They comment that the comparison to Japan of 1% is conservative.

They might have argued that uptake in the US could be lower because the US price is so much higher, but pricing has been tested and it is the payers that will pick up much of the tab. So I have assumed the $BOT folk know what they are doing on pricing, given the experience of the team.

Anyway, I’m all set and less than 4 weeks for news one way or another. Should we pass approval, I’m assuming there will be more coverage, and all talk of $0.33 will be consigned to history.